HUE034996T2 - Ivabradin-hidroklorid IV-es forma - Google Patents

Ivabradin-hidroklorid IV-es forma Download PDF

Info

Publication number
HUE034996T2
HUE034996T2 HUE12766056A HUE12766056A HUE034996T2 HU E034996 T2 HUE034996 T2 HU E034996T2 HU E12766056 A HUE12766056 A HU E12766056A HU E12766056 A HUE12766056 A HU E12766056A HU E034996 T2 HUE034996 T2 HU E034996T2
Authority
HU
Hungary
Prior art keywords
legalább legalább
ivabradine hydrochloride
ivabradine
hydrochloride
defined above
Prior art date
Application number
HUE12766056A
Other languages
English (en)
Inventor
Lopez Rafel Prohens
Vallet Cristina Puigjaner
Caòero Rafael Barbas
Rio Pericacho Jose Luis Del
Via Josep Marti
Original Assignee
Urquima Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46934559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE034996(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urquima Sa filed Critical Urquima Sa
Publication of HUE034996T2 publication Critical patent/HUE034996T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (3)

  1. IVÂllRÂOIMIÔROKi,OKID IV-ES FORMA Szahadahm igénypontok 1, b .mrumn-bcörnkimid l\-cs fonna, noels eg> okán poy-r'mrgt-ud'fftskei'ívut ,,utsgeb.d „powder X-ray diffraction”) rendelkezik, amely a következő 2-théts fok (.* 0.2 > csúcsokkal tendelkec:k >-,7-1 15,^, 1",I7, 1^,8^ és .bhöfo the·' ? iomgendr'ftAl-eio t uku sugárzás alkalma/’Ai.a\?l ',,m mérve X Ivabradiu-hidroklorid IV-es fonna az I. igénypont szerint amely egy olyan por-letttgendrtiiAkeno.ö modelkivV, ΑΠινΙι a kowtkc/o 2 íheta tok -, * 0?! csúcsokkal rendelkezik: 8.11, 8.74, 15,55, 17,17, 19,lk, 19,89, 21,82, 22/10. 24,29 és 24,53, ahol a röntgend!brake tő CuKo. sugárzás alkalmazásával van mérve, 3, I",ab:achmbtötok-otté Λ-es homa ,r 1 »ags 2 \eer\podók vnsmcl\f\e ,-,/-,1mt cmeO kg\ olyan por-rontgunhíftakcmval wodetkczih, rosnt amthcn lényegében a ' ! ábian ' au ábrázolva. 4, h ib:a,ï5n4vdo'kh'rO D es fonoa az 1 -fol S -'g igénypontok ó trsneb, ike szenei amely egy olyun Du terein, tabs Pásztázó K tfoiímefr.n termogtannmrl (angolai „DdTercnttal Scanning Calorimetry thermogram”) rendelkezik, amely egy endotenn csúccsal (angolul: vu to h». u s pea\u'twILeui 1-Vf tol mt ( „ 5, ls,ihvx(nn'!odto\h'"d ik-e* h<'t'.ta az 1 told g sgcneoontok harmehtfo sz<mn, au'tb, egy olyan Differenciális Pásztázó Kaiorimetria tenir ogr;mum.il rendelkezik, mint amilyen lényegében a 2. ábrán van ábrázolva.
  2. 6, Eljárás az. I.-töl 5.-ig igénypontok bármelyike szerinti ís^abradin-hidrokíorid IV-es forrna előállítására., ahol az. magában foglalja a következő lépést; a> jvubradin-hidroklorid szuszpendálása (angolul; „slurrying”) egy oldószer-rendszerben, ahol az oldószer-rendszer a következőket tartalmazza: toluol, etanol, acélon, melil-etil-keton, melildzobutil-keton, efil-aeetát, izopropil-acetáí és azok keverékei. I b nas a o tgervpom scettnt, ahol ac oides,e* tetu’szet ae legesben íatmima teátok és egy második oldószert, amely a következők közöl van választva: etanol, acélon és etil* acetát, vagy az a toluol. 8, 1 boros a o igcmpont sceimp ahol a hőmérséklet az ta) lépésben alacsonyabb, nom 60cC, előnyösen 10°C és 60°C között van, előnyösebben Itk'C és 30°C között van, és még előnyösebben 2O'JC és 25°C között vau. 9. au ws. nouns ,e,uJy a \,nefke/oket ι,ίΓΑΐη,ΑΖζ t ,ο I \Ί a ’pun r,Aomok bármelyike szerinti ivabradiu-hidroklorid IV-es formát és legalább egy gyógyászat tlag elfogadható segédanyagot (e.xcipienst) lő, G\og\as.-,ut készítmény a igénypont szermt orabs ad omlásta, és ahol uz előnyösen f.g\ ftlmbe\ luntfu tab'en ásták a torta yab„n all fetuleike 'este H, Gvogvaszati készítmény a 9. vagy 10. igénypontok bármelyike szemű, ahol a nevezett készítmény körülbelül 5 tng-tól körülbelül 9 sng-íg ivabradm-hidrokiorid IV-cs formát tartalmaz, es Jonyosen kómíbehtí 5,3^0 mg r,abtadm-lmirokiend IV-es format \ag\ kerülhetni 'yPS? mg ixabtadn-atdroklomt IV-es tóimat hatalmaz.
  3. 12, Eljárás a 9,-töl II -tg igénypontok bármelyike szerinti készítménynek az előállítására, azzal jelitnu'ZYt, hogy a reiezeh ehatas mamiban toitlal a u koret\C/o \c':mkd alk.Vm'4,as,u; direkt kompresszió (közvetlen préselés), száraz granulálás és/vugy nedves granttktlas 13« Eljárás a 12. igénypont szerint, azzal jellemezve, hogy a nedves granulálási eljárás magában foglalja szerves oldószereknek, előnyősön acetonnak, alkoholoknak vagy azok kombinációjának. az alkalmazását. H h ibmdt bobok'ess. ÍV s emm r í oi > g teetoroe.k batn'Jvlo \ -, i g\eg' ,o va kevmoem a 0 ό1 U g igetu-por.ok -'enni, lot tptaban tomme alkalmazásra. B habiadét 'bob olios d l\ ", loon* ee to' ' ,g tge'onontok ouiiit mm g'.moam.m 1 évin nem a *-<' 4,0 π og igénypontok x.m^oo, a lo\mke, vkoek a kezeimében tömve atka;utazásra: bradikatdia (lassú szívverés), tnlokardiabs iszkésnia, szopravenlnktdáris ritmuszavarok, krónikus stabil angina pectoris koszorúér-betegségtől szenvedő felnőtteknél. amelyeknek normális szinoszriímustik van, míokardiális infarktus, s »eCegteiersep es azokhoz kapmo’ódó ntmoszavarok
HUE12766056A 2011-11-04 2012-09-21 Ivabradin-hidroklorid IV-es forma HUE034996T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11382339.7A EP2589594A1 (en) 2011-11-04 2011-11-04 Ivabradine hydrochloride Form IV

Publications (1)

Publication Number Publication Date
HUE034996T2 true HUE034996T2 (hu) 2018-05-02

Family

ID=46934559

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12766056A HUE034996T2 (hu) 2011-11-04 2012-09-21 Ivabradin-hidroklorid IV-es forma

Country Status (21)

Country Link
US (3) US9139531B2 (hu)
EP (3) EP2589594A1 (hu)
JP (3) JP6359971B2 (hu)
KR (1) KR102050117B1 (hu)
AU (1) AU2012331395B2 (hu)
BR (1) BR112014010767B1 (hu)
CA (1) CA2854549C (hu)
CY (1) CY1119798T1 (hu)
DK (1) DK2773620T3 (hu)
ES (1) ES2562843T3 (hu)
HR (1) HRP20171511T1 (hu)
HU (1) HUE034996T2 (hu)
LT (1) LT2773620T (hu)
MX (1) MX359288B (hu)
PL (1) PL2773620T3 (hu)
PT (1) PT2773620T (hu)
RS (1) RS56464B1 (hu)
RU (1) RU2619121C2 (hu)
SI (1) SI2773620T1 (hu)
WO (1) WO2013064307A1 (hu)
ZA (1) ZA201403073B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP3156399A1 (en) * 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
ITMI20130684A1 (it) * 2013-04-24 2014-10-25 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
HRP20200300T4 (hr) 2013-03-19 2023-09-15 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida i metoda za njegovu pripremu
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es) 2013-12-12 2019-03-20 Synthon Bv Composicion farmaceutica que comprende ivabradina amorfa.
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
GR1008821B (el) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US11294199B2 (en) 2017-09-19 2022-04-05 Mitsui Chemicals, Inc. Eyewear
US20230181472A1 (en) * 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
ATE544754T1 (de) * 2006-11-30 2012-02-15 Cadila Healthcare Ltd Verfahren zur herstellung von ivabradinhydrochlorid
WO2008125006A1 (fr) * 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
WO2008146308A2 (en) 2007-05-30 2008-12-04 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
CN101597261A (zh) 2008-06-06 2009-12-09 北京深蓝海生物医药科技有限公司 无定形盐酸伊伐布雷定
US20100323471A1 (en) 2008-08-21 2010-12-23 Applied Materials, Inc. Selective Etch of Laser Scribed Solar Cell Substrate
CN101768117B (zh) 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101463008A (zh) 2009-01-11 2009-06-24 山东鲁抗辰欣药业有限公司 盐酸伊伐布雷定无定型物及其制备方法
CN101805289A (zh) 2009-02-17 2010-08-18 成都威克药业有限责任公司 伊伐布雷定盐酸盐的ω-晶型、其制备方法和药物组合物
CN102050784B (zh) 2009-11-04 2014-07-09 扬子江药业集团北京海燕药业有限公司 一种无定型盐酸伊伐布雷定的制备方法
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP3156399A1 (en) * 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride

Also Published As

Publication number Publication date
US20140315890A1 (en) 2014-10-23
KR20140101753A (ko) 2014-08-20
WO2013064307A1 (en) 2013-05-10
EP2773620A1 (en) 2014-09-10
PT2773620T (pt) 2017-10-19
RS56464B1 (sr) 2018-01-31
SI2773620T1 (sl) 2017-11-30
EP2773620B1 (en) 2017-08-16
HRP20171511T1 (hr) 2017-11-17
CA2854549C (en) 2019-08-27
EP2589594A1 (en) 2013-05-08
ES2562843T3 (es) 2017-10-19
MX2014005362A (es) 2015-01-22
BR112014010767B1 (pt) 2021-03-09
PL2773620T3 (pl) 2017-12-29
KR102050117B1 (ko) 2020-01-08
EP3263556A1 (en) 2018-01-03
DK2773620T3 (en) 2017-10-09
CA2854549A1 (en) 2013-05-10
BR112014010767A2 (pt) 2017-06-13
JP2018123154A (ja) 2018-08-09
US20150344435A1 (en) 2015-12-03
US20160289192A1 (en) 2016-10-06
LT2773620T (lt) 2017-10-25
CY1119798T1 (el) 2018-06-27
JP6359971B2 (ja) 2018-07-18
RU2014122261A (ru) 2015-12-10
AU2012331395B2 (en) 2016-11-17
JP2014532673A (ja) 2014-12-08
MX359288B (es) 2018-09-20
ES2562843T1 (es) 2016-03-08
US9309201B2 (en) 2016-04-12
JP2017178965A (ja) 2017-10-05
AU2012331395A1 (en) 2014-05-22
ZA201403073B (en) 2015-03-25
US9139531B2 (en) 2015-09-22
RU2619121C2 (ru) 2017-05-12

Similar Documents

Publication Publication Date Title
HUE034996T2 (hu) Ivabradin-hidroklorid IV-es forma
US20230322680A1 (en) Crystalline forms of pitavastatin calcium
EP3792258B1 (en) Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition
US8754129B2 (en) Crystalline vorinostat form VI
US20200283381A1 (en) Solid state forms of elafibranor
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
MC MK et al. 08184 Palau-solità i Plegamans Barcelona (ES)
WO2019053491A1 (en) CRYSTALLINE BENIDIPINE HCL SOLID FORMS AND PROCESSES FOR PREPARING THE SAME